|
gptkbp:instanceOf
|
gptkb:drug
hypnotic
imidazopyridine
|
|
gptkbp:approvalYear
|
1992
|
|
gptkbp:approvedBy
|
gptkb:FDA
|
|
gptkbp:ATCCode
|
N05CF02
|
|
gptkbp:availableOn
|
extended-release tablet
immediate-release tablet
oral spray
sublingual tablet
|
|
gptkbp:bioavailability
|
70%
|
|
gptkbp:brand
|
gptkb:Ambien
gptkb:Edluar
gptkb:Stilnox
gptkb:Zolpimist
gptkb:Intermezzo
|
|
gptkbp:CASNumber
|
82626-48-0
|
|
gptkbp:chemicalClass
|
imidazopyridine
|
|
gptkbp:contraindication
|
gptkb:myasthenia_gravis
sleep apnea
respiratory depression
severe liver impairment
|
|
gptkbp:discoveredBy
|
gptkb:Synthelabo
|
|
gptkbp:drugInteraction
|
gptkb:rifampicin
gptkb:beer
gptkb:fluvoxamine
gptkb:CNS_depressants
gptkb:ketoconazole
|
|
gptkbp:eliminationHalfLife
|
2-3 hours
|
|
gptkbp:excretion
|
urine
|
|
gptkbp:hasMolecularFormula
|
C19H21N3O
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
Zolpidem
|
|
gptkbp:KEGGID
|
D08602
|
|
gptkbp:legalStatus
|
prescription only
|
|
gptkbp:mechanismOfAction
|
GABA-A receptor agonist
|
|
gptkbp:MedlinePlusID
|
a693025
|
|
gptkbp:MeSH_ID
|
D019695
|
|
gptkbp:metabolism
|
liver
|
|
gptkbp:notABenzodiazepine
|
true
|
|
gptkbp:overdoseSymptoms
|
coma
respiratory depression
excessive sedation
|
|
gptkbp:patentExpired
|
2007
|
|
gptkbp:pregnancyCategory
|
C (US)
|
|
gptkbp:PubChem_CID
|
5732
5527
CHEMBL446
DB00425
|
|
gptkbp:riskFactor
|
abuse
withdrawal
dependence
|
|
gptkbp:routeOfAdministration
|
oral
|
|
gptkbp:sideEffect
|
gptkb:center
diarrhea
hallucination
dizziness
headache
drowsiness
|
|
gptkbp:UNII
|
7K383OQI23
|
|
gptkbp:usedFor
|
insomnia
|
|
gptkbp:WHOModelListOfEssentialMedicines
|
true
|
|
gptkbp:bfsParent
|
gptkb:Schedule_IV
gptkb:Nonbenzodiazepine_hypnotics
|
|
gptkbp:bfsLayer
|
6
|